Bright Minds Biosciences Inc. Stock Analysis & AI Score
Bright Minds Biosciences Inc. (DRUG) has an ST Score of 54.9 (B-), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $182.50 price target (+241.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Bright Minds Biosciences Inc. (DRUG) has an ST Score of 54.9 (B-), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $182.50 price target (+241.1% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthF
All factor grades
- Financial StrengthA+
- ProfitabilityA
- ForecastA
- ValuationB
- MomentumC
- GrowthF
- Piotroski1/9
Contact
DRUG stock: frequently asked questions
What is DRUG's ST Score?
Bright Minds Biosciences Inc. (DRUG) has an ST Score of 54.9 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is DRUG a buy, hold, or sell?
Analysts rate DRUG a Buy, with a price target of $182.50 (+241.1% vs the current price). Our ST Score grades it B- (54.9/100). The ST Score is a data-driven signal, not a recommendation.
What are DRUG's factor grades?
Valuation B, Profitability A, Financial Strength A+, Momentum C, Growth F, Forecast A.
What is DRUG's valuation grade?
Bright Minds Biosciences Inc. (DRUG) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is DRUG's growth grade?
Bright Minds Biosciences Inc. (DRUG) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is DRUG's profitability grade?
Bright Minds Biosciences Inc. (DRUG) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is DRUG's financial strength grade?
Bright Minds Biosciences Inc. (DRUG) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for DRUG?
The average analyst price target for Bright Minds Biosciences Inc. (DRUG) is $182.50 from 4 analysts, which is +241.1% versus the recent price of $53.51.
What is DRUG's Piotroski score?
Bright Minds Biosciences Inc. (DRUG) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.